Ramasamy Thilagavathi
Ramasamy Thilagavathi publishes mostly in Organic Chemistry, Molecular Biology and Computational Theory and Mathematics, on topics such as Computational Drug Discovery Methods, Synthesis and biological activity and Curcumin's Biomedical Applications.
- World rank
- #1,137,707 of 7,710,434 ranked researchers
- Rank in United States
- #366,839 of 1,627,098
- Works
- 52
- Citations
- 1.9k
- Citations per work
- 36.5
What does Ramasamy Thilagavathi research?
Ramasamy Thilagavathi's work is mostly in Biochemistry, Genetics and Molecular Biology (20%), Chemistry (18%), Computer Science (13%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Everything else2037.8%
- Physical Sciences1631.1%
- Chemistry917.9%
- Computer Science713.2%
- Life Sciences1019.9%
- Health Sciences611.2%
- Medicine611.2%
- 1Organic Chemistry18% of their works
- 2Molecular Biology15% of their works
- 3Computational Theory and Mathematics13% of their works
- 4Pharmacology7% of their works
- 5Molecular Medicine5% of their works
- 6Oncology5% of their works
Research topics
- Computational Drug Discovery Methods
- Synthesis and biological activity
- Curcumin's Biomedical Applications
- Inflammatory mediators and NSAID effects
- Crystallization and Solubility Studies
- PARP inhibition in cancer therapy
- Chemical Synthesis and Reactions
- Synthesis and Characterization of Heterocyclic Compounds
Which keywords describe Ramasamy Thilagavathi's research?
The keywords of their largest research topics: Medicinal Chemistry, Pharmacokinetics, Molecular Docking, Drug Target Identification, Virtual Screening, Anticancer Agents, Heterocyclic Compounds and Cancer.
- Synthesis
- Catalysis
- Nucleation
- BRCA Mutation
- Cyclooxygenase-2 Inhibitors
- Bioavailability
- Cancer
- Anticancer Agents
- Drug Target Identification
- Pharmacokinetics
- Medicinal Chemistry
- Molecular Docking
- Virtual Screening
- Heterocyclic Compounds
- Inflammation
- Curcumin
- Prostaglandins
- Crystallization
- PARP Inhibitors
- Oxidation
- Triazines
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 21 words, with their numbers
- Medicinal Chemistry342 topics
- Pharmacokinetics282 topics
- Molecular Docking232 topics
- Drug Target Identification201 topic
- Virtual Screening201 topic
- Anticancer Agents141 topic
- Heterocyclic Compounds141 topic
- Cancer132 topics
- Inflammation132 topics
- Bioavailability81 topic
- Curcumin81 topic
- Cyclooxygenase-2 Inhibitors51 topic
- Prostaglandins51 topic
- BRCA Mutation41 topic
- Crystallization41 topic
- Nucleation41 topic
- PARP Inhibitors41 topic
- Catalysis31 topic
- Oxidation31 topic
- Synthesis31 topic
- Triazines31 topic
Where does Ramasamy Thilagavathi work?
Ramasamy Thilagavathi's main affiliation in the publication record is Texas Southern University, United States.
How many publications and citations does Ramasamy Thilagavathi have?
OpenAlex counts 52 works and 1,897 citations for Ramasamy Thilagavathi, an h-index of 21, ranking #1,137,707 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Ramasamy Thilagavathi. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.